Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer

Pancreatology

Volumn 7, Issue 2-3, 2007, Pages 167-173

  Matsumoto, Gaku ^a,b   Muta, Mariko ^a   Tsuruta, Koji ^a   Horiguchi, Shinichiro ^a   Karasawa, Katsuyuki ^a   Okamoto, Atsutake ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b Migita Hospital   (Japan)

Author keywords

Angiogenesis; COX 2 expression; Liver metastases; Pancreatic cancer; Prognostic factors, pancreatic cancer; Radiation therapy, pancreatic cancer; Recurrence, pancreatic cancer; Resection, pancreatic cancer; Tumor size

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CORRELATIONAL STUDY; FEMALE; FISHER EXACT TEST; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LIVER METASTASIS; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS CANCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 34447641408     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000104241     Document Type: Article

References (44)

1. Gudjonsson B: Carcinoma of the pancreas: critical analysis of costs, results of resection, and the need for standardized reporting. J Am Coll Surg 1995;181:483-503.
2. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004;28:219-230.
3. Zerbi A, Fossati V, Parolini D: Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 1994;73:2930-2935.
4. Farrell TJ, Barbot DJ, Rosato FE: Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Ann Surg 1997;226:66-69.
5. Okamoto A, Tsuruta K, Isawa T: Intraoperative radiation therapy for pancreatic carcinoma. The choice of treatment modality. Int J Pancreatol 1994;16:157-164.
6. Okamoto A, Tsuruta K, Karasawa K: Resection versus palliation: treatment of stage III and IVA carcinomas of the pancreas employing intraoperative radiation. World J Surg 2003;27:599-605.
7. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW; European Study Group for Pancreatic Cancer: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
8. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I: An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 1993;72:2118-2123.
9. Ishikawa O, Ohigashi H, Sasaki Y: Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 1994;168:361-364.
10. Beger HG, Link KH, Gansauge F: Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective study. Hepatogastroenterology 1998;45:638-643.
11. Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M, Ochiai T, Ochiai A: Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer 2002;94:1894-1901.
12. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Hase R, Takahashi R, Mega S, Shichinohe T, Kawarada Y, Itoh T, Okushiba S, Kondo S, Katoh H: Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004;64:3533-3537.
13. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88:2239-2245.
14. Sobin LH, Wittekind C: TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002.
15. Toi M, Ueno T, Matsumoto H, Saji H, Funata N, Koike M, Tominaga T: Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 1999;5:1131-1137.
16. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74-85.
17. Fortner JG, Kimstra DS, Senie RT, Maclean BJ: Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996;223:147-153.
18. Arii S, Mori A, Uchida S, Fujimoto K, Shimada Y, Imamura M: Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999;12:25-30.
19. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
20. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, Post S: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002;25:122-129.
21. Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, Yamazaki Y: Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 2001;92:1788-1797.
22. Takao S, Takebayashi Y, Che X, Shinchi H, Natsugoe S, Miyadera K, Yamada Y, Akiyama S, Aikou T: Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas. Clin Cancer Res 1998;4:1619-1624.
23. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Büchler MW, Korc M: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309-1316.
24. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423.
25. Elder DJ, Paraskeva C: COX-2 inhibitors for colorectal cancer. Nat Med 1998;4:392-393.
26. Ishizaki T, Katsumata K, Tsuchida A, Wada T, Mori Y, Hisada M, Kawakita H, Aoki T: Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med 2006;17:357-362.
27. Smakman N, Kranenburg O, Vogten JM, Bloemendaal AL, van Diest P, Borel Rinkes IH: Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Clin Cancer Res 2005;11:41-48.
28. Nishikawa M, Stapleton PP, Freeman TA, Gaughan JP, Matsuda T, Daly JM: NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. J Am Coll Surg 2004;199:428-435.
29. Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM: Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 2004;90:712-719.
30. Matsunaga N, Yamada N, Ohira M, Tachimori A, Nishiguchi Y, Nishino H, Seki S, Hirakawa K: Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. Oncol Rep 2004;11:167-171.
31. Fenwick SW, Toogood GJ, Lodge JP, Hull MA: The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 2003;125:716-729.
32. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT: Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2003;2:1-7.
33. Levitt RJ, Pollak M: Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res 2002;62:7372-7376.
34. Merati K, Said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV: Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001;24:447-452.
35. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM: Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005;11:1618-1628.
36. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H: Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004;64:3334-3343.
37. Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K: Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 2002;35:1117-1124.
38. Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD: Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 2002;6:838-843.
39. Eibl G, Reber HA, Wente MN, Hines OJ: The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 2003;26:33-41.
40. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yoshida S: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-338.
41. Ding XZ, Tong WG, Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000;20:2625-2631.
42. Ferrari V, Valcamonico F, Amoroso V, Simoncini E, Vassalli L, Marpicati P, Rangoni G, Grisanti S, Tiberio GA, Nodari F, Strina C, Marini G: Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2006;57:185-190.
43. Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ: Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 2004;3:1217-1224.
44. Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F: Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133-138.